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ABSTRACT 
 Influenza viruses are enveloped viruses with segmented RNA genome surrounded by a 
helical symmetry shell.  Due to genetic reassortment between avian, swine, and human influenza 
viruses, a global pandemic may emerge, calling for new methods of mass vaccine production.  
Yeast is an ideal organism to express viral antigens (e.g. hemagglutinin) because of its natural 
adjuvant activity, making the expressed proteins more immunogenic when administered to the 
human body [1,2].  In addition to the purpose of vaccination, yeast is economically convenient 
by expressing proteins in a fast, inexpensive manner [3,4].  In this study, the goal is to express 
the HA1 fragment of the hemagglutinin protein from swine influenza (H1N1) virus [A/Cali/4/09] 
on the surface of yeast stain S. cerevisiae using a reconstructed shuttle vector, pYD5. 
Development of recombinant yeast cells consisted of ligating genetic sequence of HA1 into 
pYD5, transforming into E.coli cells, and electroporating DNA plasmids into EBY100 S. 
cerevisiae cells. Primary antibody for the flu strain was used in conjunction with a fluorescing 
secondary antibody, allowing visual analysis under a microscope. In result, surface expression of 
HA1 fragment was demonstrated by immunofluorescence microscopy. This study represents the 
first steps in the generation of yeast-based vaccines for the protection of influenza viruses.  
1. INTRODUCTION 
In late March and early April of 2009, a swine-origin influenza virus emerged out of Mexico 
and within weeks, spread worldwide to 30 countries and in result,   the World Health 
Organization (WHO) raised the level of influenza pandemic alert from phase 5 to phase 6 in June 
of 2009 [5,6]. The pandemic 2009 H1N1 virus is a swine-origin, influenza type A virus that 
encodes 11 proteins on eight segments of RNA [7].  The key protein that elicits prompt immune 
3 
 
response is hemagglutinin (HA) [8].  HA is responsible for binding to cellular receptors and 
fusion of the viral membranes, causing replication and transcription of viral RNAs and infecting 
the host [9].   More specifically, the HA protein binds to the host cell receptor, sialic acid [10]. 
Humans express sialyl-transferases in mucosal and respiratory tissues, resulting in N-glycans 
with α2,6 sialic acids.  However, avian species contain N-glycans linked with α2,3 sialic acids 
[11].  The varying conformations restrict viruses to specific hosts, meaning that human influenza 
viruses do not replicate in birds, and vice versa.  Swine, on the other hand, contain both α2,6 and  
α2,3 receptors in their tracheal epithelial cells, making them susceptible to human and avian 
influenza viruses [12-14].  Consequently, pigs can be seen as the “mixing” vessel for human, 
avian, and swine influenza strains, thus creating a triple reassortant virus [11,15]. The 2009 
H1N1 swine influenza virus is an example of a triple reassortant virus, as in can be outlined in 
Figure 1.   
 
Figure 1. Lineage of the 2009 H1N1 Swine Influenza Virus.  Influenza A viruses have RNA segments that encode 11 proteins 
including surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) and virulence factors NS1 (host interferon 
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antagonist) and PB1-F2 (proapoptotic factor).  The 2009 H1N1 swine influenza virus contains proteins from swine, avian, and 
human influenza viruses, making it classified as a triple reassortant virus.  Figure taken from Taia Wang [11].  
The most severe influenza A pandemic occurred in 1918, causing 20-25 million deaths and 
affecting an estimated 50% of the world population [5,16,17].  Although also spread worldwide, 
the 2009 H1N1 was milder in nature than the 1918 pandemic, which caused similar mortality 
rates that of seasonal influenza viruses (affects 10% of the world population, causing 1 million 
deaths annually worldwide) [9,18].  Pandemics and/or outbreaks arise when novel HA proteins 
emerge to which humans have no immunity [19-22].  There are 15 different subtypes of HA that 
can be differentiated both antigenically and genetically [7].  Also, HA can undergo antigenic 
drift and antigenic shift.  Antigenic drift is the gradual accumulation of point mutation in the 
protein and is responsible for yearly re-evaluation of the seasonal influenza vaccines [7,23].  
Antigenic shift is a more complex form of genetic and antigenic change in which two or more 
viruses strains combine to form a new subtype.  This may occur because of interspecies 
transmission or through genetic mutations between a current circulating virus and one or more 
new viruses [21,24,25].  Both methods of antigenic shift have been documented among influenza 
viruses [26-29].  With eight independents segments of RNA, there are 256 possible genotypes 
from two parental viruses, which make a strain with no human immunity a possible outcome.  In 
case of a pandemic event, mass amounts of vaccines must be produced.   
Currently, most influenza vaccines are produced in embryonated hens’ eggs [30,31].  The 
viruses are allowed to naturally reassort in the embryonated eggs and reassortants with the 
desired characteristics (e.g. HA and neuraminidase gene) are selected [32]. This process is 
monitored by the WHO, which houses centers in Australia, Japan, the UK, and the USA.  
Investigators analyze the epidemiology of circulating influenza viruses that are isolated from 
humans and animals and make recommendations on which strains humans are likely to be 
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infected with [33,34].  The manufacturing processes of egg-based vaccines are time consuming 
and require millions of eggs, resulting in at least a six month production cycle [33].  It is 
estimated that in the event of a worldwide pandemic, current influenza vaccine strategies will 
only cover ~17% of the worldwide population in 1 year [35].  At this rate, it would take 5 years 
to cover 100% of the world population for one influenza strain.  In addition, highly pathogenic 
avian influenza (H5N1) cannot be grown in embryonated hens’ eggs [36,37] , prevailing new 
methods of mass production in case of a severe global pandemic [38].  
A technology that has been used for production of human therapeutic proteins is yeast.  
Products such as Actrapid by NovoNordisk contain the therapeutic protein, insulin, utilizing 
Saccharomyces cerevisiae as an expression system [39,40] . Pharmaceutical companies like 
Genencor and Novoenzymes hoYeaRuse large-scale fermentation facilities for yeast propagation 
[39,41] .  Also, the number of published studies using yeast as surface display systems for 
proteins has increased almost exponentially since the late 1990s [42]. Yeasts are commonly 
utilized because they meet safety issues (i.e. do not harbor pathogens, viral inclusions, or 
pyrogens [43]), have rapid growth rate in simple media, and are able to secrete and modify 
recombinant proteins [43-47].  Also known as baker’s yeast, S. cerevisiae has been in use the 
longest, leading to a complete mapping of its genome in 1996 and the first eukaryote applied to 
heterologous gene expression [43,48,49]. S. cerevisiae will be used in this study as a host 
organism for surface display of the HA1 domain of the 2009 H1N1 HA protein, and more 
specifically the virus strain H1N1//Cali/4/09 (provided by St. Louis Children Hospital).  The HA 
protein consists of HA1 and HA2 segments, but HA1 forms the large globular head of the 
protein that contains the receptor binding and antigenic sites, to which the immune system 
responds to [7,50-54].  
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For creation of recombinant yeast cells, “shuttle” vectors are generally used.  Shuttle vectors 
are hybrids between yeast-derived and bacterial sequences [43,46].  The reason for this strategy 
is to maximize efficiency (e.g. DNA plasmids can be extracted from ampicillin resistant 
recombinant E.coli cells) [46,55-57].  E.coli has been used in previous studies to allow rapid 
propagation of recombinant cells and plasmids are then extracted from E.coli cells and 
electroporated into yeast cells [58-63]. An available yeast shuttle vector that is commercially 
available is vector pYD1, provided by Invitrogen, originally developed by Boder and Wittrup 
[64]. In the pYD1 vector, the protein of interested is flanked on the N-terminus by mating protein 
Aga2, which binds to surface membrane Aga1 protein by disulfide bonds. However, it was 
discovered by Dr. Z. Wang that the vector could be reconstructed to increase affinity to protein 
of interest by leaving the NH2 terminus of the displayed protein of interest free, rather than 
protein of interest being sterically hindered [65]. The new yeast display vector is named pYD5. 
A visual image can be depicted in Figure 2.  
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Figure 2. Schematic of the commercially available yeast display vector pYD1 (Invitrogen) in which the displayed protein 
is tethered at its N-terminus to Aga2p mating protein through the Xpress epitope and a (G4S)3 linker (left) and the rebuilt 
vector pYD5 in the reverse orientation, where the protein of interest’s N-terminus is free (right). Picture taken from Z. 
Wang [65].  
 This study describes the creation of an EBY100 S. cerevisiae strain expressing the HA1 
domain of the hemagglutinin antigen of the H1N1 virus, A/Cali/4/09.  The methods consist of (1) 
amplifying DNA of the HA1 domain gene sequence, (2) ligating plasmid DNA into expression 
shuttle vector, pYD5, (3) transforming of pYD5-HA1 into competent E. coli cells, and (4) 
electroporating plasmid DNA into EBY100 cells. Because an important key factor for the 
production of heterologous proteins is the transcription efficiency of the genes, an inducible 
promoter, 2% galactose, will be used to maintain yeast cultures for optimal transcription 
maintenance [46,66].  
2. MATERIALS AND METHODS 
 
2.1 Plasmids, bacterial and yeast strains, antibodies 
H1N1 HA plasmid fragment (pHW2000/H1N1/A/Cali/4/09) was obtained courtesy of St. 
Louis Children Hospital.  Full sequence genome (available from NCBI Influenza Virus Resource 
database) of the HA protein can be found in Appendix 1. The HA1-domain is highlighted in 
yellow and is 981 base pairs long.  S. cerevisiae strain cells, EBY100 was procured from 
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Invitrogen. pYD5 yeast display vector was obtained Dr. Z. Wang (NIH, Bethesda, MD).   
Competent 5-alpha E.coli cells were purchased from New England Biolabs.  Monoclonal anti-
influenza virus H1 hemagglutinin (HA) antibody was obtained from BEI Resources.  Secondary 
Goat Anti-mouse IgG was purchased from Thermo Scientific.   
2.2 PCR amplification of HA1 domain of H1N1 (pHW2000/H1N1/A/Cali/4/09) and gel 
electrophoresis analysis 
With the help of Dr. Qing-long Liang, forward and reverse primers were designed.  Forward 
primer, pYD5-H1N1-HA1-F read 5’-
CTAGCTAGCGTTTTAGCAGCTGGTGACACATTATGTATAG-3’ and reverse primer pYD5-
H1N1-HA1-R read 5’CCGGAATTCTCTAGATTGAATAGAC-3’.  The underlined portions are 
recognition sites for restriction endonucleases enzymes NheI and EcoRI, respectively.  The kit 
used for PCR was Phusion High Fidelity PCR KIT (NEB, MA).  According to the protocol, PCR 
optimization is enhanced when template DNA (plasmid pHW2000/H1N1/A/Cali/4/09) is at 10 
ng/µL.  The concentration of the plasmid was determined by a microplate spectrophotometer 
from BioTek and adjusted to 10 ng/µL.  For 50 µL reactions: 10 µL of 5x Phusion HF buffer, 1 
µL of 10 mM dNTPS, 2.5 µL of 10 µM forward and reverse primers, 1 µL of template DNA, 0.5 
µL of Phusion DNA polymerase, and 32.5 µL of nuclease free water were added.  Cycling 
conditions were as follows: 1 cycle of initial denaturation at 98 °C for 30 seconds, 35 cycles of 
98 °C for 10 seconds, 45 °C for 30 seconds, and 72 °C for 1 minute, and 1 cycle of 72 °C for 10 
minutes.  The PCR product was then analyzed via gel electrophoresis (100 volts for 40 minutes) 
using 1x TAE buffer, 0.8% agarose, and ethidium bromide solution.  
9 
 
2.3 Extraction of DNA from gel and double enzyme digestion and ligation 
The DNA fragment from the agarose gel was extracted using Qiagen Qiaquick Gel 
Extraction protocol.  To digest the restriction enzymes and cut the double-stranded DNA to its 
proper sequence, restriction enzymes EcoRI and NheI were used.  The protocol of double 
enzyme digestions consisted of: 2 µL of NEB Buffer 1 (10x), 0.5 µL of BSA (100x), 1 µL of 
NheI (10,000 U/mL), 0.5 µL of EcoRI (20,000 U/mL), and 16 µL of purified gel-extracted DNA 
products.  The mixture was placed in a 37 °C water bath for 2 hours.  The digested DNA product 
was then purified again using Qiagen Gel Extraction kit.  The purified DNA product was then 
ligated into pYD5 yeast display vector in accordance to the protocol DNA ligation with T4 DNA 
Ligase (Fisher Scientific; USA).      
2.4 Transformation of pYD5-HA1-H1N1into competent E. coli cells and PCR bacterial analysis 
The ligation product was transformed to NEB 5-alpha competent E.coli cells using the High 
Efficiency Transformation protocol (NEB, USA).  Recombinant E. coli cells were then spread 
onto LB plates (1.0% Tryptone, 0.5% Yeast Extract, 1% NaCl, and 100µg/mL of ampicillin).  
The plates were placed in a 37 °C incubator overnight.  After overnight incubation, single 
colonies were isolated and mixed with 10 µL of nuclease-free water.  1 µL of the solution was 
then used as a template for PCR, while the remaining 9µL of positive clones solution tested by 
PCR were mixed with 5 ml of LB media (with ampicillin) and placed in a shaking (250 rpm) 
incubator at 37 °C overnight. 
2.5 Extraction of plasmid from E.coli and double enzyme digestion and sequencing for 
confirmation of positive clones 
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To isolate the plasmid DNA from E.coli, the Pureyield Plasmid Miniprep System protocol 
was used (Promega; San Luis Obispo, CA).  Product were then digested enzymatically again 
using EcoRI and NheI.  Samples were sent to the department of Poultry Science for sequencing.  
2.6 Electroporation of DNA plasmid into EBY100 yeast vector and induction 
Plasmid DNA was electroporated into S. cerevisiae strain EBY100 using the Mircopulser 
Electroporation Apparatus (Bio-Rad; Hercules, CA) following the “Electroporation of S. 
cerevisiae” protocol from the provided manual [67]. In the manual, it was suggested to 5-100 ng 
of plasmid DNA sample, and the selected amount was 100 ng.  Electroporated product was then 
spread onto Minimal Dextrose (MD) plates that contained 0.01% leucine and incubated at 30 °C.  
This media allows for single yeast colonies to grow in 3 days (pYD1 Yeast Display Vector Kit; 
Invitrogen).  After 3 day incubation period, two single yeast colonies (pYD5-HA1-1 and pYD-
HA-2) were inoculated into 10 mL YNB-CAA growth medium containing 2% glucose as a 
carbon source (pYD1 Yeast Display Vector Kit; Invitrogen).  Flasks were placed in a shaking 
incubator at 30 °C overnight. Plasmids were extracted from yeast cells and the extractant were 
used as templates for PCR to determine if the HA1 fragment was in the yeast clones. Protocol 
and kit used was from Zymoprep Yeast Plasmid Miniprepartion Kit I (Zymo Research; Irvine, 
CA).  Cell cultures were then subjected to modification until correct OD600 readings resulted 
(following “Induction” protocol from pYD1 Yeast Display Vector; Invitrogen).  Cell cultures 
were incubated at 20 °C with shaking.  To determine the optimal induction time for maximum 
display, the cell cultures were assayed over a 68 hour time period and samples were stored at 4 
°C for fluorescence immunostaining.  Yeast cells were induced by 2% galactose (pYD1 Yeast 
Display Vector Kit; Invitrogen).  
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2.7 Test HA1expression using fluorescence immunostaining  
After the 72 hour sample was collected, all time point samples were centrifuged at 3000-
5000g for 10 minutes at 4° C. Cells were resuspended in 1x PBS buffer and centrifuged at same 
speed and time length  After aspiration of PBS, the cell pellets were resuspended in 250 µL of 
1X PBS, 1 mg/ml BSA, and 1 µg of monoclonal anti-HA (H1N1/Cali/4/09) antibody.  Samples 
were placed on at 4 °C for one hour with occasional mixing.  Samples were centrifuged again at 
same speed and time length.  Cells were then washed with 1 mL of 1X PBS.  After aspiration of 
PBS, cells were resuspended in 250 µL of 1X PBS, 1 mg/mL BSA, and 0.5 µL goat anti-mouse 
IgG conjugated with fluorescein isthiocyanate (FITC) secondary antibody.  This secondary 
antibody will conjugate with the primary antibody and fluoresce under microscope, giving 
confirmation of expression of HA1 domain of HA protein.  Samples were incubated at 4 °C for 
30 minutes in the dark with occasional inverting of tubes. Samples were then washed two times 
with 1 mL of 1X PBS (no BSA) and were finally resuspended in 40µL of 1X PBS, where a 5 µL 
aliquot was placed on a slide and observed under a 400X fluorescing imaging microscope 
(Olympus; PA).  
3. RESULTS 
3.1 PCR results of HA1 domain of pHW2000/H1N1/A/Cali/4/09 
The plasmid concentration of the HA fragment using the spectrophotometer was 167 ng/µL. 
A 2 µL aliquot was diluted with 33.4 µL of H20 to result in an optimized concentration of 10 
ng/µL.   The HA1 domain of the strain is approximately 981 base pairs.  The following figure 
(Figure 3) shows the gel electrophoresis product, with a specific band being right under the 1 
kilo-base marker.  
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Figure 3. Gel Electrophoresis Analysis of HA1 domain of H1N1 strain pHW2000/H1N1/A/Cali/4/09 
 Agarose gel electrophoresis of PCR amplification of HA1 domain of H1N1 strain, pHW2000/H1N1/A/Cali/4/09. From the 
NCBI database, the HA1 domain 981 base pairs long,  and the PCR product is right under the 1 kilo-base pair marker.   
3.2 Double enzyme digestion of plasmid DNA extracted from E. coli 
After the pYD5 vector containing HA1 had been transformed into E.coli and plasmid 
DNA had been recovered, double enzyme reaction was done to determine if a specific DNA 
band could be noticed after gel electrophoresis.   Figure 4. shows the results of gel product.  The 
specific band at right around 1 kb shows that HA1 fragment (981 bp) was able to be isolated 
from vector and E.coli.  The genetic sequence (acquired from Poultry Science) is listed in 
Appendix 2.  Alignment of obtained genetic sequence from Poultry Science and sequences from 
NCBI Influenza Virus Resource database is consistent and correct.  
HA1 
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Figure 4. Gel electrophoresis after double enzyme digestion 
Gel electrophoresis product after double enzyme digestion. The bottom specific band confirms that the HA1 fragment is 
detectable at around 981 bp.  
3.3 Electroporation product and extracted plasmid from yeast 
Data of the electroporated yeast cells and plasmid extraction from yeast were not obtained.  
However, PCR analysis of plasmid DNA extracted from the yeast cells did indeed have a 
specific band at 981 bp. Image not shown.   
3.4 Immunofluorescence staining 
Recombinant yeast cells expressing the HA1 fragment of HA protein are distinguished in 
fluorescence microscopy by emitting green color.   Induction times were at 0 hr (control), 24 hr, 
48 hr, and 68 hr.  The images can be seen in Figure 5.  The label FITC signifies only the cells 
that emitted protein expression. A FITC and BF image was also taken at time point to show the 
relationship between expressed cells and non-expressed cells. After induction with 2% galactose, 
it usually takes about 4 hours to detect expression, so the control sample at 0 hr does not show 
protein expression. The Yeast Display Vector Kit from Invitrogen had estimated that optical 
induction time would be between 24-48 hours. From the images, there is an increase in the 
number of expressed cells from 24 to 48 hours.  However, from 48-68 hour, there was not an 
increase in expressed cells.  To determine statistical analysis of expressed cells, flow cytometry 
HA1 
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will need to be done, which is an experiment in the works and the results have not been 
documented.  
 
       
      
      
Figure 5. Immunofluorescence microscopy  
 Immunofluorescence using primary antibody that reacts with HA1 fragment of the HA protein of H1N1 virus and a 
secondary antibody that reacts with primary antibody.  From the pYD1 Yeast Display Vector Kit from Invitrogen, it 
states that optimal detection should occur between 12 and 48 hours.  The Aga2p fusion can be detected as early as 4 hours 
after the switch to galactose, so the 0 hour control confirms that there is no expression signal.  The images suggest that 
cells at 48 hour induction time was slightly better than 24 hour induction time, but further analysis such as flow 
cytometry would need to be conducted.  However, there is no statically significance between 48 hour and 68 hour 
induction time, suggesting that optimal expression is indeed between 12-48 hours.  (BF: Brighfield)     
4. DISCUSSION 
Since the HA1 subunit of HA contains most of its antigenic sites, the work presented was to 
determine if the subunit could successfully be expressed in yeast for the purpose of developing 
vaccines.  By determining the nucleotides and code length of the HA1 subunit, PCR analysis 
would confirm if HA1 could be detected after manipulations with E.coli and S. cerevisiae. DNA 
plasmid extractions from both E.coli and S. cerevisiae did contain the HA1 subunits in gel 
electrophoresis products, affirming that the strategy of using both hosts does increase efficiency.  
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The immunofluorescence staining results demonstrate that the primary antibody does attach to 
the HA1 fragment antigen. Moreover, it is likely that the express proteins in yeast cells do retain 
their proper confirmations, although further tests must be conducted for confirmation. Ideally, 
the goal is for all yeast cells to express the protein, which is not seen by immunofluorescence 
staining.  To maximize cell expression, further research in modification of media should be 
conducted. Also, it was noted in the literature that optimal induction time was between 24 and 48 
hr. To find the most optimal time, it would be a good idea to have several more time periods (e.g. 
32 and 40 hr).   
In summary, the hypothesis of yeast cells being able to express the HA1 fragment of HA was 
positive.  Although further details, such as calculating the concentration of expressed protein and 
determining optimal concentration for immunization, this study represents a first step in the 
production of yeast-based vaccines for influenza viruses.   
5. CONCLUSION 
5.1 Current Status 
In this study, HA1 subunit from a strain of swine influenza was expressed on the cell surface 
of S. cerevisiae. Immunofluorescence demonstrated the localization of the HA1 subunit on the 
surface of yeast. Although there are many more steps involved for the construction of a vaccine, 
the time-scale in creating recombinant yeast cells is significantly shorter than that of egg-based 
vaccines.  Typically, S. cerevisiae fermentations take 5 days from start to finish: 2 days for 
inoculum development, 1 day for biomass accumulation on glucose, and ~2 days for galactose 
induction [66]. For egg-based vaccines, there is at least a 3-month lead time for the start of 
production [31].  
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5.2 Future Directions 
To measure the ratio of expressed and non-expressed recombinant yeast cells, flow 
cytometry of the sample must be conducted. Also, to calculate the molecular weight of the HA1 
fragment, a Western Blot assay must also be conducted.  Then measures can be taken into 
calculating the concentration of the antigen secreted and construction of a proper dosage vaccine 
for mouse immunizations.  The postdoctoral associates, Dr. Qing-Long Liang and Dr. Han Lei 
have constructed a similar expression system; however, they are using highly pathogenic avian 
influenza virus subtype (H5N1) In addition, they have constructed yeast cells that not only 
contain the antigenic HA protein, but also conjugated with CD154, a protein that is primary 
expressed on activated T cells (for increased immune response).  They are currently undergoing 
mouse immunization.  
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8. APPENDICES 
7.1: Appendix 1: HA1 sequence of HA protein 
A/Cali/4/09 (H1N1) – HA sequence from NCBI Influenza Virus Resource database 
Highlighted portion is HA1 domain-981 bp 
AGCAAAAGCAGGGGAAAATAAAAGCAACAAAAATGAAGGCAATACTAGTAGTTCT
GCTATATACATTTGCAACCGCAAATGCAGACACATTATGTATAGGTTATCATGCGAA
CAATTCAACAGACACTGTAGACACAGTACTAGAAAAGAATGTAACAGTAACACACT
CTGTTAACCTTCTAGAAGACAAGCATAACGGGAAACTATGCAAACTAAGAGGGGTA
GCCCCATTGCATTTGGGTAAATGTAACATTGCTGGCTGGATCCTGGGAAATCCAGAG
TGTGAATCACTCTCCACAGCAAGCTCATGGTCCTACATTGTGGAAACACCTAGTTCA
GACAATGGAACGTGTTACCCAGGAGATTTCATCGATTATGAGGAGCTAAGAGAGCA
ATTGAGCTCGGTGTCATCATTTGAAAGGTTTGAGATATTCCCCAAGACAAGTTCATG
GCCCAATCATGACTCGAACAAAGGTGTAACGGCAGCATGTCCTCATGCTGGAGCAA
AAAGCTTCTACAAAAATTTAATATGGCTAGTTAAAAAAGGAAATTCATACCCAAAG
CTCAGCAAATCCTACATTAATGATAAAGGGAAAGAAGTCCTCGTGCTATGGGGCATT
CACCATCCATCTACTAGTGCTGACCAACAAAGTCTCTATCARAATGCARATACATAT
GTTTTTGTGGGGTCATCAAGATACAGCAAGAAGTTCAAGCCGGAAATAGCAATAAG
ACCCAAAGTGAGGGATCAAGAAGGGAGAATGAACTATTACTGGACACTAGTAGAGC
CGGGAGACAAAATAACATTCGAAGCAACTGGAAATCTAGTGGTACCGAGATATGCA
TTCGCAATGGAAAGAAATGCTGGATCTGGTATTATCATTTCAGATACACCAGTCCAC
GATTGCAATACAACTTGTCAAACACCCAAGGGTGCTATAAACACCAGCCTCCCATTT
CAGAATATACATCCGATCACAATTGGAAAATGTCCAAAATATGTAAAAAGCACAAA
ATTGAGACTGGCCACAGGATTGAGGAATATCCCGTCTATTCAATCTAGAGGCCTATT
TGGGGCCATTGCCGGTTTCATTGAAGGGGGGTGGACAGGGATGGTAGATGGATGGT
ACGGTTATCACCATCAAAATGAGCAGGGGTCAGGATATGCAGCCGACCTGAARAGC
ACACAGAATGCCATTGACGAGATTACTAACAAAGTAAATTCTGTTATTGAAAAGAT
GAATACACAGTTCACAGCAGTAGGTAAAGAGTTCAACCACCTGGAAAAAAGAATAG
AGAATTTAAATAAAAAAGTTGATGATGGTTTCCTGGACATTTGGACTTACAATGCCG
AACTGTTGGTTCTATTGGAAAATGAAAGAACTTTGGACTACCACGATTCAAATGTGA
AGAACTTATATGAAAAGGTAAGAAGCCAGCTAAAAAACAATGCCAAGGAAATTGG
AAACGGCTGCTTTGAATTTTACCACAAATGCGATAACACGTGCATGGAAAGTGTCAA
AAATGGGACTTATGACTACCCAAAATACTCAGAGGAAGCAAAATTAAACAGAGAAG
AAATAGATGGGGTAAAGCTGGAATCAACAAGGATTTACCAGATTTTGGCGATCTATT
CAACTGTCGCCAGTTCATTGGTACTGGTAGTCTCCCTGGGGGCAATCAGCTTCTGGA
TGTGCTCTAATGGGTCTCTACAGTGTARAATATGTATTTAACATTAGGATTTCARAA
GCATGAGAAAAACACCCTTGTTTCTACT 
7.2 Appendix 2: Genetic sequence of DNA plasmid extracted from E.coli 
Sample 1 
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NNNNNNNNNNNNTTNNTACNTTTTCATTAAGATGCAGTTACTTCGCTGTTTTTCAAT
ATTTTCTGTTATTGCTNNCGTTTTAGCAGCTGGTGACACATTATGTATAGGTTATCAT
GCGAACAATTCAACAGACACTGTAGACACAGTACTAGAAAAGAATGTAACAGTAAC
ACACTCTGTTAACCTTCTAGAAGACAAGCATAACGGGAAACTATGCAAACTAAGAG
GGGTAGCCCCATTGCATTTGGGTAAATGTAACATTGCTGGCTGGATCCTGGGAAATC
CAGAGTGTGAATCACTCTCCACAGCAAGCTCATGGTCCTACATTGTGGAAACACCTA
GTTCAGACAATGGAACGTGTTACCCAGGAGATTTCATCGATTATGAGGAGCTAAGA
GAGCAATTGAGCTCGGTGTCATCATTTGAAAGGTTTGAGATATTCCCCAAGACAAGT
TCATGGCCCAATCATGACTCGAACAAAGGTGTAACGGCAGCATGTCCTCATGCTGGA
GCAAAAAGCTTCTACAAAAATTTAATATGGCTAGTTAAAAAAGGAAATTCATACCC
AAAGCTCAGCAAATCCTACATTAATGATAAAGGGAAAGAAGTCCTCGTGCTATGGG
GCATTCACCATCCATCTACTAGTGCTGACCAACAAAGTCTCTATCAGAATGCAGATA
CATATGTTTTTGTGGGGTCATCAAGATACAGCAAGAAGTTCAAGCCGGAAATAGCA
ATAAGACCCAAAGTGAGGGATCAAGAAGGGAGAATGAACTATTACTGGACACTAGT
AGAGCCGGGAGACAAAATAACATTCGAAGCAACTGGAAATCTAGTGGTACCGAGAT
ATGCATTCGCAATGGAAAGAAATGCTGGATCTGGTATTATCATTTCAGATACACCAG
TCCACGATTGCAATACAACTTGTCAAACACCCNANGGGTGCTATAAACACCAGCCTC
CCATTTCANAATATACATCCGATCACAATTGGAAAATGTCCAAAATATGTAAAAAGC
ACAAANNGANACTGNNNNCNGNATTGANNNNNTCCCNNCTATTCNATCNANAANA
ANTNGGNANNNNTNCCNNNNCCNNNNCNNNGNNNNNNNATNNNNNNNNNNNNNN
NNNNNNNGNNNNNNNNGNNNNNNNNNNNNNNNNNNNNNNNNNNNGNNN 
Sample 2 
NNNNNNNNNNNTTNNNACNTTTTCATTAAGATGCAGTTACTTCGCTGTTTTTCNATA
TTTTCTGTTATTGCTAGCGTTTTAGCAGCTGGTGACACATTATGTATAGGTTATCATG
CGAACAATTCAACAGACACTGTAGACACAGTACTAGAAAAGAATGTAACAGTAACA
CACTCTGTTAACCTTCTAGAAGACAAGCATAACGGGAAACTATGCAAACTAAGAGG
GGTAGCCCCATTGCATTTGGGTAAATGTAACATTGCTGGCTGGATCCTGGGAAATCC
AGAGTGTGAATCACTCTCCACAGCAAGCTCATGGTCCTACATTGTGGAAACACCTAG
TTCAGACAATGGAACGTGTTACCCAGGAGATTTCATCGATTATGAGGAGCTAAGAG
AGCAATTGAGCTCGGTGTCATCATTTGAAAGGTTTGAGATATTCCCCAAGACAAGTT
CATGGCCCAATCATGACTCGAACAAAGGTGTAACGGCAGCATGTCCTCATGCTGGA
GCAAAAAGCTTCTACAAAAATTTAATATGGCTAGTTAAAAAAGGAAATTCATACCC
AAAGCTCAGCAAATCCTACATTAATGATAAAGGGAAAGAAGTCCTCGTGCTATGGG
GCATTCACCATCCATCTACTAGTGCTGACCAACAAAGTCTCTATCAGAATGCAGATA
CATATGTTTTTGTGGGGTCATCAAGATACAGCAAGAAGTTCAAGCCGGAAATAGCA
ATAAGACCCAAAGTGAGGGATCAAGAAGGGAGAATGAACTATTACTGGACACTAGT
AGAGCCGGGAGACAAAATAACATTCGAAGCAACTGGAAATCTAGTGGTACCGAGAT
ATGCATTCGCAATGGAAAGAAATGCTGGATCTGGTATTATCATTTCAGATACACCAG
TCCACGATTGCAATACAACTTGTCAAACACCCNANGGGTGCTATAAACACCAGCCTC
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CCATTTCANAANATACATCCGATCACNATTNGAAAATGTCCAAAATATGTAAAAAG
CACAAAATNGANACTGNNNNCNGNATNGNNNNNTCCCGNCNATTCNNTCNNNAAN
AANNNNNNANNNNNTNNNNNNNNNNNCNNNNNNNNNANNNNNNNNNNNNGGNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
 
 
 
 
